PreciseDx Secures $20.7M to Improve Diagnostics in Oncology Using AI Technology nextdigitalhealth.com

PreciseDx, a pioneering medical technology leveraging the power of artificial intelligence (AI) to improve diagnostics in oncology, has secured $20.7 million in a series B funding round to accelerate growth and expansion.

Co-founded in 2020 by Jack Zeineh MD, and Gerardo Fernandez MD, the company’s latest financing round was spearheaded by Eventide Asset Management, supported by contributions from Quest Diagnostics, GenHenn Capital Venture, Labcorp, and existing investors. The new capital brings PreciseDx’s total funding to $31.5 million since its launch.